Biden Administration Urged To Prioritize Sustainable Access
As The Association Launches ‘Secure Our Meds’ Campaign
Executive Summary
The AAM has unveiled its policy priorities for sustainable access to generics and biosimilars for the newly elected US president Joe Biden’s administration and the 117th Congress. The association has also launched a new advocacy campaign called “Secure Our Meds,” kicking off with a report on “Securing Sustainable Markets.”
You may also be interested in...
AAM CEO Urges President-Elect Biden To Act On Access
Laying out the 2021 outlook for US generics and biosimilars, AAM president and CEO Dan Leonard has urged US president-elect Joe Biden and lawmakers in the US Congress to act to maximize savings and access to medicines.
AAM Welcomes US Access Bill
The AAM has backed the draft Protecting Access to Affordable Medicines Act of 2020 introduced by the US House of Representatives members GK Butterfield, Billy Long and Tony Cardenas and has urged House members to co-sponsor the bill, which aims to protect low-cost generic medicines from a “misguided” Medicaid penalty.
US Saves $313bn From Generics And $2.2bn From Biosimilars
The AAM’s 2019 report titled ‘Securing Our Access & Savings’ throws light on the monumental savings and benefits of generics and biosimilars for US patients and other stakeholders. The report urges policymakers to act to address obstacles to the off-patent industry and brings industry’s COVID-19 response in perspective again.